Infection with the hepatitis C virus may result in chronic liver disease for which no effective therapy is now available. We studied the effects of recombinant human interferon alfa in a prospective, randomized, double-blind, placebo-controlled trial in patients with well-documented chronic hepatitis C. Forty-one patients were enrolled in the trial, 37 of whom were later found to have antibody to hepatitis C virus. Twenty-one patients received interferon alfa (2 million units) subcutaneously three times weekly for six months, and 20 received placebo. The mean serum aminotransferase levels and the histologic features of the liver improved significantly in the patients treated with interferon but not in the patients given placebo. Ten patients treated with interferon (48 percent) had a complete response, defined as a decline in mean serum aminotransferase levels to the normal range during therapy; three others had a decrease in mean aminotransferase levels of more than 50 percent. After treatment ended, however, serum aminotransferases usually returned to pretreatment levels; 6 to 12 months after the discontinuation of interferon therapy, only two patients (10 percent) still had normal values. We conclude that interferon alfa therapy is beneficial in reducing disease activity in chronic hepatitis C; however, the beneficial responses are often transient.
AM Di Bisceglie ,P Martin ,C Kassianides ,M Lisker-Melman ,L Murray ,J Waggoner ,Z Goodman ,SM Banks ,JH Hoofnagle
Source Information
Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.
This article has been cited by other articles:
Khader, Y. S., Dweek, A., Alkafajei, A., Rabi', A. Z.
(2006). Combination Therapy of Interferon and Ribavirin Versus Interferon Monotherapy in Treatment of Chronic Hepatitis C: A Meta-analysis of Clinical Trials. Journal of Pharmacy Practice
19: 265-274
[Abstract]
Wang, C.-Q., Li, Y., Douglas, S. D., Wang, X., Metzger, D. S., Zhang, T., Ho, W.-Z.
(2005). Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression. Am. J. Pathol.
167: 1333-1340
[Abstract][Full Text]
Moorman, J., Saad, M., Kosseifi, S., Krishnaswamy, G.
(2005). Hepatitis C Virus and the Lung: Implications for Therapy. Chest
128: 2882-2892
[Abstract][Full Text]
Takahashi, M., Saito, H., Higashimoto, M., Atsukawa, K., Ishii, H.
(2005). Benefit of Hepatitis C Virus Core Antigen Assay in Prediction of Therapeutic Response to Interferon and Ribavirin Combination Therapy. J. Clin. Microbiol.
43: 186-191
[Abstract][Full Text]
Yoshida, H, Tateishi, R, Arakawa, Y, Sata, M, Fujiyama, S, Nishiguchi, S, Ishibashi, H, Yamada, G, Yokosuka, O, Shiratori, Y, Omata, M
(2004). Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut
53: 425-430
[Abstract][Full Text]
Li, Y., Zhang, T., Douglas, S. D., Lai, J.-P., Xiao, W.-D., Pleasure, D. E., Ho, W.-Z.
(2003). Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression. Am. J. Pathol.
163: 1167-1175
[Abstract][Full Text]
Ramos-Casals, M., Trejo, O., Garcia-Carrasco, M., Font, J.
(2003). Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford)
42: 818-828
[Full Text]
Reddy, S. I., Ukomadu, C.
(2003). Viral Hepatitis and Hepatocellular Carcinoma in African Americans. Cancer Epidemiol. Biomarkers Prev.
12: 248S-251
[Full Text]
Lauer, G. M., Walker, B. D.
(2001). Hepatitis C Virus Infection. NEJM
345: 41-52
[Full Text]
Bonacini, M., Puoti, M.
(2000). Hepatitis C in Patients With Human Immunodeficiency Virus Infection: Diagnosis, Natural History, Meta-analysis of Sexual and Vertical Transmission, and Therapeutic Issues. Arch Intern Med
160: 3365-3373
[Abstract][Full Text]
Schafer, D. F., Sorrell, M. F.
(2000). Conquering Hepatitis C, Step by Step. NEJM
343: 1723-1724
[Full Text]
SOMA, J., SAITO, T., TAGUMA, Y., CHIBA, S., SATO, H., SUGIMURA, K., OGAWA, S., ITO, S.
(2000). High Prevalence and Adverse Effect of Hepatitis C Virus Infection in Type II Diabetic-Related Nephropathy. J. Am. Soc. Nephrol.
11: 690-699
[Abstract][Full Text]
Munoz, A E, Levi, D, Podesta, A, Gorin, J M., Gonzalez, J, Bartellini, M A, Munne, M S, Cabanne, A, Flichman, D, Terg, R
(2000). Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial. Gut
46: 427-431
[Abstract][Full Text]
Campistol, J. M., Esforzado, N., Martinez, J., Rosello, L., Veciana, L., Modol, J., Casellas, J., Pons, M., de las Cuevas, X., Piera, J., Oliva, J. A., Costa, J., Barrera, J. M., Bruguera, M.
(1999). Efficacy and tolerance of interferon-{alpha}2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant
14: 2704-2709
[Abstract][Full Text]
Vogt, M., Lang, T., Frosner, G., Klingler, C., Sendl, A. F., Zeller, A., Wiebecke, B., Langer, B., Meisner, H., Hess, J.
(1999). Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening. NEJM
341: 866-870
[Abstract][Full Text]
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S., Yamada, G., Omata, M., for the IHIT Study Group,
(1999). Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. ANN INTERN MED
131: 174-181
[Abstract][Full Text]
Cresta, P, Musset, L, Cacoub, P, Frangeul, L, Vitour, D, Poynard, T, Opolon, P, Nguyen, D-T, Golliot, F, Piette, J-C, Huraux, J-M, Lunel, F
(1999). Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut
45: 122-128
[Abstract][Full Text]
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Shiota, G., Harada, K.-i., Ishida, M., Tomie, Y., Okubo, M., Katayama, S., Ito, H., Kawasaki, H.
(1999). Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis
20: 59-63
[Abstract][Full Text]
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., Albrecht, J., The International Hepatitis Interventional Therapy,
(1998). Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. NEJM
339: 1493-1499
[Abstract][Full Text]
Imai, Y., Kawata, S., Tamura, S., Yabuuchi, I., Noda, S., Inada, M., Maeda, Y., Shirai, Y., Fukuzaki, T., Kaji, I., Ishikawa, H., Matsuda, Y., Nishikawa, M., Seki, K., Matsuzawa, Y.
(1998). Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C. ANN INTERN MED
129: 94-99
[Abstract][Full Text]
Polyak, S. J., McArdle, S., Liu, S.-L., Sullivan, D. G., Chung, M., Hofgartner, W. T., Carithers, R. L. Jr., McMahon, B. J., Mullins, J. I., Corey, L., Gretch, D. R.
(1998). Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection. J. Virol.
72: 4288-4296
[Abstract][Full Text]
Hayashi, J., Kishihara, Y., Ueno, K., Yamaji, K., Kawakami, Y., Furusyo, N., Sawayama, Y., Kashiwagi, S.
(1998). Age-Related Response to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection. Arch Intern Med
158: 177-181
[Abstract][Full Text]
Kim, W. R., Poterucha, J. J., Hermans, J. E., Therneau, T. M., Dickson, E. R., Evans, R. W., Gross, J. B. Jr.
(1997). Cost-Effectiveness of 6 and 12 Months of Interferon-{alpha} Therapy for Chronic Hepatitis C. ANN INTERN MED
127: 866-874
[Abstract][Full Text]
Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., Kilani, A., Areias, J., Auperin, A., Benhamou, J. P., Degott, C., Erlinger, S.
(1997). Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-{alpha} Therapy. ANN INTERN MED
127: 875-881
[Abstract][Full Text]
Hoofnagle, J. H., Di Bisceglie, A. M.
(1997). The Treatment of Chronic Viral Hepatitis. NEJM
336: 347-356
[Full Text]
Sharara, A. I., Hunt, C. M., Hamilton, J. D.
(1996). Hepatitis C. ANN INTERN MED
125: 658-668
[Abstract][Full Text]
Chemello, L., Cavalletto, L., Casarin, C., Bonetti, P., Bernardinello, E., Pontisso, P., Donada, C., Belussi, F., Martinelli, S., Alberti, A.
(1996). Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon-{alpha} in Chronic Hepatitis C. ANN INTERN MED
124: 1058-1060
[Abstract][Full Text]
Hoofnagle, J. H., Lau, D.
(1996). Chronic Viral Hepatitis -- Benefits of Current Therapies. NEJM
334: 1470-1471
[Full Text]
Dusheiko, G M, Khakoo, S, Soni, P, Grellier, L
(1996). Fortnightly Review: A rational approach to the management of hepatitis C infection. BMJ
312: 357-364
[Abstract][Full Text]
Di Bisceglie, A. M., Conjeevaram, H. S., Fried, M. W., Sallie, R., Park, Y., Yurdaydin, C., Swain, M., Kleiner, D. E., Mahaney, K., Hoofnagle, J. H.
(1995). Ribavirin as Therapy for Chronic Hepatitis C: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED
123: 897-903
[Abstract][Full Text]
Matsumori, A., Matoba, Y., Sasayama, S.
(1995). Dilated Cardiomyopathy Associated With Hepatitis C Virus Infection. Circulation
92: 2519-2525
[Abstract][Full Text]
Shindo, M., Arai, K., Sokawa, Y., Okuno, T.
(1995). Hepatic Hepatitis C Virus RNA as a Predictor of a Long-Term Response to Interferon-{alpha} Therapy. ANN INTERN MED
122: 586-591
[Abstract][Full Text]
Gerberding, J. L.
(1995). Management of Occupational Exposures to Blood-Borne Viruses. NEJM
332: 444-451
[Full Text]
Nousbaum, J.-B., Pol, S., Nalpas, B., Landais, P., Berthelot, P., Brechot, C., The Collaborative Study Group*,
(1995). Hepatitis C Virus Type 1b (II) Infection in France and Italy. ANN INTERN MED
122: 161-168
[Abstract][Full Text]
Di Bisceglie, A. M.
(1994). Interferon Therapy for Chronic Viral Hepatitis. NEJM
330: 137-138
[Full Text]
Koretz, R. L., Abbey, H., Coleman, E., Gitnick, G.
(1993). Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade. ANN INTERN MED
119: 110-115
[Abstract][Full Text]
Johnson, R. J., Gretch, D. R., Yamabe, H., Hart, J., Bacchi, C. E., Hartwell, P., Couser, W. G., Corey, L., Wener, M. H., Alpers, C. E., Willson, R.
(1993). Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection. NEJM
328: 465-470
[Abstract][Full Text]
Gorman, S. E., Plaisance, K.
(1991). Application of Products Produced Through Biotechnology in Infectious Diseases. Journal of Pharmacy Practice
4: 103-116
(1989). INTERFERON ALPHA FOR CHRONIC HEPATITIS C. JWatch General
1989: 3-3
[Full Text]
Previous
